

VIRTUAL SYMPOSIUM

ICNMDigital

2020

**New insights in
the use of intravenous
immunoglobulins:**

How to enhance CIDP
patients' clinical
outcomes?

e-Sympo
Saturday September, 12
13:00 CET

Chairman:


Eduardo Nobile-Orazio

Speakers:

Helmar Lehmann

Yusuf Rajabally

Eduardo Nobile-Orazio



New insights in the use of intravenous immunoglobulins: How to enhance CIDP patients' clinical outcomes?

Chairman:
Eduardo Nobile-Orazio

Speakers:
Helmar Lehmann - Yusuf Rajabally
Eduardo Nobile-Orazio

PROGRAM

Predicting the response to intravenous immunoglobulins in patients with CIDP

Helmar Lehmann, Germany

Individualized IVIg treatment as an optimization of therapeutic strategy in CIDP

Yusuf Rajabally, UK

A European efficacy and safety study of IVIg 10% in the treatment of patients with CIDP: The PRISM Study results

Eduardo Nobile-Orazio, Italy

This presentation was approved by Scientific Program Committee as independent activity held in conjunction with the ICNMDigital. This presentation is not sponsored or endorsed by ICNMDigital.



LFB BIOMEDICAMENTS

Limited company with a capital of 150 000 000 Euros - 491 371 167 RCS EVRY
3, avenue des Tropiques - BP 40305 - 91958 Courtaboeuf Cedex - France
Phone: +33 (0)1 69 82 70 10 - Fax: +33 (0)1 69 07 19 03
www.groupe-lfb.com